Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma

@article{Kawaguchi2007TargetingEA,
  title={Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma},
  author={Yoshihiko Kawaguchi and Koji Kono and Kousaku Mimura and Fumihiko Mitsui and Hidemitsu Sugai and Hidenori Akaike and Hideki Fujii},
  journal={British Journal of Cancer},
  year={2007},
  volume={97},
  pages={494 - 501}
}
We previously reported that oesophageal squamous cell carcinoma (SCC) had a relatively high incidence of EGFR and HER-2 overexpression. Thus, anti-HER family targeting may become a promising approach to treat oesophageal SCC. In the present study, we investigated (a) the distribution of EGFR and HER-2 expression in oesophageal SCC (n=66) detected by immunohistochemistry and (b) cetuximab- and/or trastuzumab-mediated biological activity (antiproliferative effect by the MTT assay, apoptosis… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico • 2016
View 5 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2006
View 1 Excerpt

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2006
View 1 Excerpt

Similar Papers

Loading similar papers…